Psoriatic Disease: Current Therapeutic Recommendations and Cost Management Considerations in Specialty Pharmacy

Release Date: June 30, 2018
Expiration Date: December 31, 2019
Estimated Time to Complete Activity: 1.5 hours
Compatible with all modern browsers and mobile devices

EXPERT FACULTY


	Robin Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA Click here for biography

	James Kenney, Jr., RPh, MBA Manager, Specialty and Pharmacy Contracts Harvard Pilgrim Health Care Click here for biography

	Alan Menter, MD Chief, Division of Dermatology Baylor University Medical Center Click here for biography

TARGET AUDIENCE

Specialty pharmacists and other managed care pharmacy professionals

STATEMENT OF NEED/PROGRAM OVERVIEW

Psoriasis and psoriatic arthritis presents a significant clinical and humanistic burden to patients. Patients diagnosed with psoriatic disease are subject to increased mortality rates and functional disability which may lead to significant impairment in quality of life and increased use of health care resources. Fortunately, there has been a marked increase in the number of safe and effective therapies to the disease. The pathologic complexity of psoriatic disease and the comorbidities frequently requires collaborative multidisciplinary care. Improved awareness of therapeutic options available to manage the spectrum of pathologic challenges confronted by patients with psoriatic disease will enable HCDMs and specialty pharmacy providers to improve patient quality of life and clinical outcomes.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

Assess current and emerging therapies for the treatment of psoriasis and psoriatic arthritis and cite their clinical trial data
Align payer driven psoriatic disease treatment algorithms with recent clinical trial data
Describe care pathways and their application as a cost management tool in psoriatic disease
Employ specialty pharmacy and disease management services for psoriatic disease patients

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008162-9999-18-083-H01-P, 1.5 contact hours (application)

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Robin Dore, MD	Contracted Research: Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Lilly USA, LLC, and Novartis Pharmaceuticals Corporation Consulting Fees (eg, Advisory Boards): Amgen, Inc., AbbVie, Inc., Lilly USA, LLC, and Novartis Pharmaceuticals Corporation Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., Speakers’ Bureau): Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Celgene Corporation, and Novartis Pharmaceuticals Corporation
James Kenney, Jr., RPh, MBA	The faculty member has nothing to disclose.
Alan Menter, MD	Advisory Board for AbbVie, Inc., Allergan Pharmaceuticals, Amgen, Inc., Boehringer Ingleheim Pharmaceuticals, Inc., Eli-Lilly, Janssen Biotech, Inc., LEO Pharma Consulting fees from AbbVie, Inc., Allergan Pharmaceuticals, Amgen Inc., Eli-Lilly, Galderma, Janssen Biotech, Inc., LEO Pharma, Novartis Pharmaceuticals Corporation, Pfizer,Inc., Vitae, Xenoport Investigator for AbbVie, Inc., Allergan Pharmaceuticals, Amgen, Inc., Anacor, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Dermira, Eli-Lilly, Janssen Biotech, Inc., LEO Pharma, Merck, Neothetics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron, Symbio / Maruho, Xenoport Speakers’ Bureau for AbbVie, Inc., Amgen, Janssen Biotech, Inc., Leo Pharma

The PIM planners and managers have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CPE credit for this activity. During the period of June 30, 2018, through December 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CPE activity, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.